Skip to main content
Premium Trial:

Request an Annual Quote

One Place Where Less Is Definitely More

According to recently published work in Nature, the Cancer Genome Atlas has revealed that many tumors are heterogeneous. More mutations might mean more drug targets, says Derek Lowe, but that's not necessarily a good thing, he writes at In the Pipeline. "Just doing the math on the possible interactions of several dozen mutations with a list of possible treatment regimes is enough to make you pause." The biggest challenge for drug discovery will be finding out what all these mutations do and how they interact with one another.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.